Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Pharma
Novo touts weight loss results in high-dose Wegovy study
In the ongoing quest to expand semaglutide’s clinical pedigree, Novo Nordisk is rolling out new data on a higher-dose injection in obesity.
Fraiser Kansteiner
Jan 17, 2025 9:40am
A $410M obesity debut, Legend, BeiGene and more—Fierce Pharma Asia
Jan 10, 2025 9:00am
Roche projected to claim pharma's 2025 sales crown: Evaluate
Jan 3, 2025 1:07pm
Lilly seeks to intervene in compounded tirzepatide lawsuit
Jan 2, 2025 4:16pm
Lilly’s Zepbound set to ‘dominate’ obesity market: GlobalData
Jan 2, 2025 10:42am
Novo, Lilly poised to overcome GLP-1 supply constraints in 2025
Dec 30, 2024 8:00am
